Labs race to make pharmaceutical MDMA available to treat mental illness

The Globe & Mail

April 15, 2023

The Globe & Mail visited the lab operated by our subsidiary Psilo Scientific and interviewed our team regarding MDMA and the Special Access Program.

read more News

Filament Health Announces Interim Results From Phase I Clinical Trial At The University Of California San Francisco

Iboga: A Promising Yet Under-Researched Psychoactive Plant

Filament Health Announces First Ever Nagoya Protocol-Compliant Shipment Of Iboga From Gabon